Orna develops treatments that cause the patient's body to generate its own cell therapy against underlying diseases.
Eli Lilly, which is battling Denmark's Novo Nordisk for dominance in the lucrative global market for diet pills, is paying cash. The price of Orna will ultimately be determined by whether the company achieves certain development milestones.
